The epidemiology of prostate cancer (2003-2017)

A recent report in the CDC’s Morbidity and Mortality Weekly Report (MMWR) may offer one of the best analyses of an increasing risk for diagnosis with and death from advanced forms of prostate cancer over the period from 2003 to 2017 (the last year for which we have accurate data from the SEER database). … READ MORE …

The PSA test in “screening” for prostate cancer: yesterday, today, and tomorrow

So our good friend Howard Wolinsky has just written up his assessment on the evolution of the use of the PSA test in “screening” for prostate cancer in an article on the MedPage Today web site. … READ MORE …

Breakthrough Device Designation for miR Sentinel™ urine test

According to a media release issued on Tuesday this week by miR Scientific, the US Food and Drug Administration (FDA) has issued a Breakthrough Device Designation for the company’s new urine-based test for risk of prostate cancer (the miR Sentinel™ Prostate Test). … READ MORE …

The virtual prostate cancer patient

A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient about their own risks for prostate cancer and things like the risks and benefits of PSA testing. … READ MORE …

Adding ADT to external beam radiation only benefits unfavorable risk patients

In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …

Risk calculators for men already on active surveillance

The Prostate Active Surveillance Study (PASS), initially funded by the Canary Foundation, is a multi-center research study for men  with low-risk disease who have chosen active surveillance (AS) to manage their prostate cancer. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. … READ MORE …

Routine testing for COVID-19 for prostate cancer patients?

An article published in Communications Biology has suggested that all prostate cancer patients should be routinely tested fro risk of infection with COVID-19. This appears to be a questionable piece of advice for the average prostate cancer patient. … READ MORE …

The pros and cons of “screening” for prostate cancer

A newly published article by Shoag et al. in the New England Journal of Medicine (NEJM) has suggested that the risks associated with “screening” for prostate cancer using the PSA test may not be as high as previously suggested. … READ MORE …

More on familial and hereditary risk for prostate cancer

Slowly but surely we are learning more about the roles of family history and familial genetics (heredity) in determining risk for prostate cancer — and most especially risk for clinically significant forms of prostate cancer. … READ MORE …

Germline testing to assess risk for specific types of prostate cancer

The recommendations of the Philadelphia Prostate Cancer Consensus Conference 2019 (held in October last year) on implementation of germline testing for risk of prostate cancer have now been published in the Journal of Clinical Oncology. … READ MORE …

Importance of adding ADT to brachy boost therapy for men with unfavorable-risk prostate cancer

Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …

Alas … PPV not good for PI-RADS at all

For the past few years, some of us have been quietly concerned about the true value of MRI scans and the accuracy of PI-RADS scores in evaluation of a patient’s risk for the presence of clinically significant prostate cancer. This is a complex issue … but data from a large, recently completed study has now validated these concerns. … READ MORE …

Focal therapy for localized prostate cancer: the “state of the art”

In a report on the UroToday web site, John Fortin, a prostate cancer patient who chose to have focal therapy himself a while ago, has reported on information presented at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held in Washington, DC, in February this year. … READ MORE …

FamGenix — a family health history app

As the Democratic Party discovered this week in Iowa, apps can have problems. However, there are also apps that prove to be very useful straight out of the gate — and they can be improved over time too. … READ MORE …

Diabetes and risk for prostate cancer

There have long been suggestions that men already diagnosed with and receiving treatment for diabetes are at lower risk for a subsequent diagnosis of prostate cancer than non-diabetics. However, a very large, new, epidemiological analysis seems to suggest strongly that this may not be the case at all. … READ MORE …